相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment
Khiem C. Lam et al.
CELL (2021)
Tumor immunological phenotype signature-based high-throughput screening for the discovery of combination immunotherapy compounds
Haiyan Wang et al.
SCIENCE ADVANCES (2021)
ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation
Mengjie Hu et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
TBK1 recruitment to STING activates both IRF3 and NF-κB that mediate immune defense against tumors and viral infections
Seoyun Yum et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer
Seung Joon Lee et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages
Zhipeng Liu et al.
CANCER LETTERS (2020)
Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy
Eva Perez-Guijarro et al.
NATURE MEDICINE (2020)
Self-assembled cGAMP-STINGΔTM signaling complex as a bioinspired platform for cGAMP delivery
Yanpu He et al.
SCIENCE ADVANCES (2020)
cGAS-STING-mediated DNA sensing maintains CD8+ T cell stemness and promotes antitumor T cell therapy
Wenwen Li et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer
Sri Krishna et al.
SCIENCE (2020)
MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS-, and NF1-Mutant Melanomas
Ophelia Maertens et al.
CANCER DISCOVERY (2019)
Cryptotanshinone has curative dual anti-proliferative and immunotherapeutic effects on mouse Lewis lung carcinoma
Shuo Liu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models
Weiqing Jing et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Inhibition of murine hepatoma tumor growth by cryptotanshinone involves TLR7-dependent activation of macrophages and induction of adaptive antitumor immune defenses
Zhen Han et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas et al.
NATURE MEDICINE (2019)
Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy
Aurelie Durgeau et al.
FRONTIERS IN IMMUNOLOGY (2018)
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
Young Kwang Chae et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, efficacy, and Limitations
Judith A. Seidel et al.
FRONTIERS IN ONCOLOGY (2018)
TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy
Christopher B. Rodell et al.
NATURE BIOMEDICAL ENGINEERING (2018)
High-mobility group nucleosome binding domain 1 (HMGN1) functions as a Th1-polarizing alarmin
De Yang et al.
SEMINARS IN IMMUNOLOGY (2018)
Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity
Kelsey E. Sivick et al.
CELL REPORTS (2018)
HMGN1 and R848 Synergistically Activate Dendritic Cells Using Multiple Signaling Pathways
Md Masud Alam et al.
FRONTIERS IN IMMUNOLOGY (2018)
Melanoma treatment in review
Beatriz Domingues et al.
IMMUNOTARGETS AND THERAPY (2018)
Therapeutic vaccine to cure large mouse hepatocellular carcinomas
Zhen Han et al.
ONCOTARGET (2017)
The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression
Julia M. Weiss et al.
ONCOIMMUNOLOGY (2017)
Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors
Yingjie Nie et al.
SCIENTIFIC REPORTS (2017)
Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses
Kelly D. Moynihan et al.
NATURE MEDICINE (2016)
Genomic Classification of Cutaneous Melanoma
Rehan Akbani et al.
CELL (2015)
STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
Juan Fu et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
Leticia Corrales et al.
CELL REPORTS (2015)
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Seng-Ryong Woo et al.
IMMUNITY (2014)
DMXAA Causes Tumor Site-Specific Vascular Disruption in Murine Non-Small Cell Lung Cancer, and like the Endogenous Non-Canonical Cyclic Dinucleotide STING Agonist, 2′3′-cGAMP, Induces M2 Macrophage Repolarization
Charlene M. Downey et al.
PLOS ONE (2014)
BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells By Reactivating MEK and ERK Signaling
Berta Sanchez-Laorden et al.
SCIENCE SIGNALING (2014)
Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response
Pia Kvistborg et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Combined p19Arf and interferon-beta gene transfer enhances cell death of B16 melanoma in vitro and in vivo
C. A. Merkel et al.
CANCER GENE THERAPY (2013)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Use of the Pharmacological Inhibitor BX795 to Study the Regulation and Physiological Roles of TBK1 and IκB Kinase ε A DISTINCT UPSTREAM KINASE MEDIATES SER-172 PHOSPHORYLATION AND ACTIVATION
Kristopher Clark et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Eosinophil-derived neurotoxin acts as an alarmin to activate the TLR2-MyD88 signal pathway in dendritic cells and enhances Th2 immune responses
De Yang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Melanoma biology and new targeted therapy
Vanessa Gray-Schopfer et al.
NATURE (2007)
High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin
De Yang et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2007)
Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines
VO Melnikova et al.
ONCOGENE (2004)
Cancer immunotherapy: moving beyond current vaccines
SA Rosenberg et al.
NATURE MEDICINE (2004)
Characterization of mouse melanoma cell lines by their mortal malignancy using an experimental metastatic model
K Nakamura et al.
LIFE SCIENCES (2002)
LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells
D Yang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)